Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
Motilal Oswal initiates coverage on Sri Lotus Developers with Rs 250 target ; stock jumps over 5%
24/09/2025
Gold prices cool off by Rs 900 from highs after Fed remarks on potential rate cuts. Will the uptrend resume ?
24/09/2025
What makes Unimech, Solar Industries & Bharat Dynamics most expensive defence stocks - should you bet ?
24/09/2025
Trump says Gaza talks 'very successful with big players' despite disagreement over Palestine state recognition
24/09/2025
Indian REITs yield higher than US, Singapore, remain compelling bet’ : Anurag Mathur
24/09/2025
Gold steady near record high as markets assess Powell's comment
24/09/2025
